{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Abumiya M"],"funding":["Japan Society for the Promotion of Science"],"pagination":["6362"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7973796"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["The purpose of this study was to investigate the effects of SLC22A2 808G>T polymorphism and trough concentrations (C<sub>0</sub>) of bosutinib on serum creatinine in 28 patients taking bosutinib. At 1, 3, 6, 12, 24, and 36 months after administration, analysis of bosutinib C<sub>0</sub> and creatinine was performed at the same time of day. Significant correlations were observed between bosutinib C<sub>0</sub> and the change rate of serum creatinine or the estimated glomerular filtration rate (eGFR; r = 0.328, P < 0.001 and r = - 0.315, P < 0.001, respectively). These correlations were particularly high in patients having the SLC22A2 808G/G genotype (r = 0.345 and r = - 0.329, respectively); however, in patients having the 808T allele, there were no significant differences. In multivariate "],"journal":["Scientific reports"],"pubmed_title":["Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy."],"pmcid":["PMC7973796"],"funding_grant_id":["20K07150"],"pubmed_authors":["Takahashi S","Yoshioka T","Miura M","Takahashi N","Abumiya M","Kameoka Y"],"additional_accession":[]},"is_claimable":false,"name":"Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy.","description":"The purpose of this study was to investigate the effects of SLC22A2 808G>T polymorphism and trough concentrations (C<sub>0</sub>) of bosutinib on serum creatinine in 28 patients taking bosutinib. At 1, 3, 6, 12, 24, and 36 months after administration, analysis of bosutinib C<sub>0</sub> and creatinine was performed at the same time of day. Significant correlations were observed between bosutinib C<sub>0</sub> and the change rate of serum creatinine or the estimated glomerular filtration rate (eGFR; r = 0.328, P < 0.001 and r = - 0.315, P < 0.001, respectively). These correlations were particularly high in patients having the SLC22A2 808G/G genotype (r = 0.345 and r = - 0.329, respectively); however, in patients having the 808T allele, there were no significant differences. In multivariate ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-25T19:22:19.795Z","creation":"2025-04-06T07:58:37.197Z"},"accession":"S-EPMC7973796","cross_references":{"pubmed":["33737618"],"doi":["10.1038/s41598-021-85757-7"]}}